Apolipoprotein E phenotype and renal disease

Contributions to Nephrology

Volumn 120, Issue , 1997, Pages 22-29

  Oda, Hiroaki ^a,b   Yorioka, Noriaki ^a   Ueda, Chikako ^a   Nishida, Yoji ^a   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GLOMERULONEPHRITIS; HUMAN; JAPAN; MALE; PHENOTYPE;

ADULT; ALLELES; APOLIPOPROTEINS E; CHOLESTEROL; FEMALE; GLOMERULONEPHRITIS; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; TRIGLYCERIDES;

EID: 0030633809     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059820     Document Type: Article

References (31)

1. Chan MK, Varghese Z, Moorhead JF: Lipid abnormalities in uremia, dialysis and transplantation. Kidney Int 1981;19:625-637.
2. Cappelli P, Evangelista M, Bonomini M, Palmieri PF, Albertazzi A: Lipids in the progression of chronic renal failure. Nephron 1992;62:31-35.
3. Norbeck HE, Carlson LA: Increased frequency of late pre-β lipoproteins (LP β) in isolated serum very low density lipoproteins in uremia. Eur J Clin Invest 1980;10:423-426.
4. Green D, Stone NJ, Krumlovsky FA: Putative atherogenic factors in patients with chronic renal failure. Prog Cardiovasc Dis 1983;26:133-144.
5. Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987;31:1153-1159.
6. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis. Am J Nephrol 1988;8:261-271.
7. Innerarity TL, Mahley RW: Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978;17:1440-1447.
8. Sherrill BC, Innerarity TL, Mahley RW: Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. J Biol Chem 1980;255:1804-1807.
9. Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, Amouyel P, Schaffer P, Ruidavetes JB, Cambien F, Fruchart JC, Ducimetiere P: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. Arterioscler Thromb 1994;14:1412-1419.
10. Kataoka S, Paidi M, Howard BV: Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem 1994;40:11-13.
11. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
12. Friedewald WT, Levy RI, Fredriekson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 1991;39(suppl 31):41-48.
14. Guijarro C, Keane WF: Lipid-induced glomerular injury. Nephron 1994;67:1-6.
15. Keane WF: Lipids and the kidney. Kidney Int 1994;46:910-920.
16. Maschio G, Oldrizzi L, Rugiu C, Loschiavo C: Serum lipids in patients with chronic renal failure on long-term, protein-restricted diets. Am J Med 1989;87:51N-54N.
17. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman PO: Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993;63:279-285.
18. Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
19. Nordestgaard BG, Stender S, Kjeldsen K: Severe hypertriglyceridemia, large lipoproteins and protection against atherosclerosis. Scand J Clin Lab Invest 1987;47(suppl 186):7-12.
20. Corbo RM, Scacchi R, Mureddu L, Mulas G, Alfano G: Apolipoprotein E polymorphism in Italy investigated in native plasma by a simple polyacrylamide gel isoelectric focusing technique: Comparison with frequency data of other European populations. Ann Hum Genet 1995;59:197-209.
21. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-440.
22. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S: Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: Influence of apolipoprotein E polymorphism. Metabolism 1996;45:63-71.
23. Utermann G, Jaeschke M, Menzel HJ: Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (apoE-II) in the very-low-density lipoproteins. FEBS Lett 1975;56:352-355.
24. Kitahara M, Shinomiya M, Shirai K, Saito Y, Yoshida S: Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese. Atherosclerosis 1990;82:197-204.
25. Weisgraber KH, Innerarity TL, Mahley RW: Abnormal lipoprotein receptor-binding activity of the human E apolipoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982;257:2518-2521.
26. Demant T, Bedford D, Packard CJ, Shepherd J: Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 1991;88:1490-1501.
27. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S: Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: Sex-specific effects. Arterioscler Thromb 1994;14:1553-1560.
28. Bergeron N, Havel RJ: Prolonged postprandial responses of lipids an apppolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein ε4 allele. J Clin Invest 1996;97:65-72.
29. Oda H, Utsumi C, Nishida Y, Yorioka N, Yamakido M: Role of apolipoprotein (Apo) E polymorphism in patients with kidney diseases (abstract). J Am Soc Nephrol 1994;5:339.
30. Stengard JH, Zebra K.E, Pekkanen J, Ehnholm C, Nissinen A, Sing CF: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265-269.
31. Oda H, Yorioka N, Ueda C, Okushin S, Kaishihata S, Nishida Y, Yamakido M: Severely decreased hepatic triglyceride lipase (HTGL) activity induces abnormal accumulation of intermediate density lipoprotein (IDL), while lipoprotein lipase (LPL) activity remains normal in dialysis patients (abstract). J Am Soc Nephrol 1995;6:585.